Harriet Mayanja-Kizza explores the clinical and immunological impact of Mycobacterium tuberculosis (MTB) on HIV-1 infection and disease. She illustrates how, unlike other HIV related opportunistic infections, successful treatment of MTB disease may in some patients be associated with some degree of decrease in HIV-1 load. However, this is partial, and not sustained, and does not halt the progress of HIV disease.
H. Mayanja-Kizza, Mycobacterium Tuberculosis and Human Immuno-Deficiency Virus Type 1 Interaction Pathogenesis and Disease Modulation in Dual Infection.
Prof. J.M.A. Lange
Prof. F.G.J. Cobelens
Dr M.L. Joloba (Makerere University College of Health Sciences, Uganda)
This event is open to the public.